Quick Answer
Nurix Therapeutics, Inc. reported Total Assets of $688.14 million for the year ending 2025.
- Nurix Therapeutics, Inc. showed an increase of +2.8% in Total Assets from 2024 to 2025.
- This data is from Nurix Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on January 28, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $411.87 million | Q1 2021: $396.66 million | Q2 2021: $517.98 million | Q3 2021: $493.07 million | Q1 2022: $437.72 million | Q2 2022: $394.31 million | Q3 2022: $459.34 million | Q1 2023: $370.15 million | Q2 2023: $350.62 million | Q3 2023: $308.20 million | Q1 2024: $312.67 million | Q2 2024: $511.03 million | Q3 2024: $513.60 million | Q1 2025: $615.04 million | Q2 2025: $591.56 million | Q3 2025: $522.47 million.
- Over the full 7 years of available data (2019 to 2025), Nurix Therapeutics, Inc.'s Total Assets has grown by 1,462.2%.
- Historical annual values: Fiscal year 2025: $688.14 million | Fiscal year 2024: $669.34 million | Fiscal year 2023: $355.60 million | Fiscal year 2022: $416.76 million | Fiscal year 2021: $476.77 million | Fiscal year 2020: $396.34 million | Fiscal year 2019: $44.05 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: